CU20200020A7 - Composición farmacéutica que comprende abx196 - Google Patents

Composición farmacéutica que comprende abx196

Info

Publication number
CU20200020A7
CU20200020A7 CU2020000020A CU20200020A CU20200020A7 CU 20200020 A7 CU20200020 A7 CU 20200020A7 CU 2020000020 A CU2020000020 A CU 2020000020A CU 20200020 A CU20200020 A CU 20200020A CU 20200020 A7 CU20200020 A7 CU 20200020A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical composition
abx196
composition including
formula
bladder
Prior art date
Application number
CU2020000020A
Other languages
English (en)
Spanish (es)
Inventor
Sandrine Crabe
Hartmut Ehrlich
Philippe Pouletty
Didier Scherrer
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax filed Critical Abivax
Publication of CU20200020A7 publication Critical patent/CU20200020A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CU2020000020A 2017-09-13 2018-09-13 Composición farmacéutica que comprende abx196 CU20200020A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306182 2017-09-13
PCT/EP2018/074778 WO2019053142A1 (en) 2017-09-13 2018-09-13 ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER

Publications (1)

Publication Number Publication Date
CU20200020A7 true CU20200020A7 (es) 2020-11-30

Family

ID=60001797

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000020A CU20200020A7 (es) 2017-09-13 2018-09-13 Composición farmacéutica que comprende abx196

Country Status (18)

Country Link
US (1) US11266667B2 (enExample)
EP (1) EP3681512B1 (enExample)
JP (1) JP7214718B2 (enExample)
KR (1) KR102706165B1 (enExample)
CN (1) CN111182907B (enExample)
AU (1) AU2018332046B2 (enExample)
BR (1) BR112020004778A2 (enExample)
CA (1) CA3075443A1 (enExample)
CU (1) CU20200020A7 (enExample)
DK (1) DK3681512T3 (enExample)
ES (1) ES2893549T3 (enExample)
HR (1) HRP20211351T1 (enExample)
IL (1) IL273054B2 (enExample)
MX (1) MX394216B (enExample)
PL (1) PL3681512T3 (enExample)
PT (1) PT3681512T (enExample)
WO (1) WO2019053142A1 (enExample)
ZA (1) ZA202001435B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022187141A1 (en) 2021-03-01 2022-09-09 Deciduous Therapeutics Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008350531B2 (en) * 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物
US9181292B2 (en) * 2011-01-05 2015-11-10 Pi-Hui Liang Methods for preparation of glycosphingolipids and uses thereof
RU2770432C2 (ru) * 2016-09-14 2022-04-18 Абивакс Комбинации для лечения рака, включающие abx196

Also Published As

Publication number Publication date
MX394216B (es) 2025-03-24
AU2018332046A1 (en) 2020-03-19
US11266667B2 (en) 2022-03-08
EP3681512A1 (en) 2020-07-22
IL273054A (en) 2020-04-30
CA3075443A1 (en) 2019-03-21
WO2019053142A1 (en) 2019-03-21
ZA202001435B (en) 2022-07-27
MX2020002812A (es) 2020-07-21
AU2018332046B2 (en) 2024-06-13
CN111182907A (zh) 2020-05-19
CN111182907B (zh) 2023-01-06
KR20200102412A (ko) 2020-08-31
IL273054B2 (en) 2023-05-01
HRP20211351T1 (hr) 2021-11-26
JP2020533368A (ja) 2020-11-19
ES2893549T3 (es) 2022-02-09
JP7214718B2 (ja) 2023-01-30
BR112020004778A2 (pt) 2020-10-13
PT3681512T (pt) 2021-10-06
KR102706165B1 (ko) 2024-09-13
IL273054B1 (en) 2023-01-01
EP3681512B1 (en) 2021-08-04
PL3681512T3 (pl) 2022-01-17
RU2020109889A (ru) 2021-09-06
DK3681512T3 (da) 2021-09-06
RU2020109889A3 (enExample) 2022-01-28
US20200230163A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2017002606A1 (es) Inhibidor de bromodominio
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
MX2019009653A (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
GT201500247A (es) Imidazopiridazinas sustituidas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
NI201800071A (es) Compuestos de isoindol
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
AR095097A1 (es) Compuestos de fenoxietoxi
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.